Candriam S.C.A. Ascendis Pharma A/S Put Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ASND
# of Institutions
236Shares Held
58.2MCall Options Held
238KPut Options Held
299K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.21 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$638 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$620 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$548 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$520 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $6.94B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...